Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 6/2020

01-06-2020 | Prostate Cancer | Original Article

Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls—results from a population-based study

Authors: Salome Adam, Daniela Doege, Lena Koch-Gallenkamp, Melissa S. Y. Thong, Heike Bertram, Andrea Eberle, Bernd Holleczek, Ron Pritzkuleit, Mechthild Waldeyer-Sauerland, Annika Waldmann, Sylke Ruth Zeissig, Lina Jansen, Sabine Rohrmann, Hermann Brenner, Volker Arndt

Published in: Supportive Care in Cancer | Issue 6/2020

Login to get access

Abstract

Background

Prostate cancer (PC) and its treatment may affect PC survivors differently with respect to age. However, little is known regarding age-specific health-related quality of life (HRQoL) in PC survivors 5 years or even ≥ 10 years post-diagnosis.

Methods

The sample included 1975 disease-free PC survivors (5–16 years post-diagnosis) and 661 cancer-free population controls, recruited from two German population-based studies (CAESAR+, LinDe). HRQoL in both populations was assessed using the EORTC QLQ-C30 questionnaire. Additionally, PC survivors completed the PC-specific EORTC QLQ-PR25 questionnaire. Differences in HRQoL between survivors and controls, as well as differences according to age and time since diagnosis were analyzed with multiple regression after adjustment for age, education, stage, and time since diagnosis, where appropriate.

Results

In general, PC survivors reported HRQoL and symptom-burden levels comparable to the general population, except for significantly poorer social functioning and higher burden for diarrhea and constipation. In age-specific analyses, PC survivors up to 69 years indicated poorer global health and social functioning than population controls. Stratification by time since diagnosis revealed little difference between the subgroups. On PC-specific symptoms, burden was highest for urinary bother and symptoms, and lowest for bowel symptoms. Younger age was associated with less urinary symptoms but higher urinary bother.

Conclusion

Long-term disease-free PC survivors reported overall good HRQoL, but experienced persistent specific detriments. Our data suggest that these detriments do not improve substantially with increasing time since diagnosis. Targeted interventions are recommended to prevent PC-related and treatment-related symptoms becoming chronic and to enhance social functioning.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH (2011) Cancer survivors: a booming population. Cancer Epidemiol Biomarkers Prev. 20(10):1996–2005CrossRef
4.
5.
6.
Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL (2017) Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. Cancer Med. 6(7):1827–1836CrossRef
7.
Adam S, Feller A, Rohrmann S, Arndt V (2018) Health-related quality of life among long-term (≥5 years) prostate cancer survivors by primary intervention: a systematic review. Health Qual Life Outcomes. 16(1):1–14CrossRef
8.
Adam S, Koch-Gallenkamp L, Bertram H, Eberle A, Holleczek B, Pritzkuleit R et al (2019) Health-related quality of life in long-term survivors with localised prostate cancer by therapy—results from a population-based study. Eur J Cancer Care (Engl). 28(5):e13076. https://​doi.​org/​10.​1111/​ecc.​13076
9.
Namiki S, Kaiho Y, Mitsuzuka K, Saito H, Yamada S, Nakagawa H et al (2014) Long-term quality of life after radical prostatectomy: 8-year longitudinal study in Japan. Int J Urol Off J Japanese Urol Assoc. 21(12):1220–1226
10.
Kerleau C, Guizard AV, Daubisse-Marliac L, Heutte N, Mercier M, Grosclaude P, Joly F, French Network of Cancer Registries (FRANCIM) (2016) Long-term quality of life among localised prostate cancer survivors: QALIPRO population-based study. Eur J Cancer. 63:143–153CrossRef
11.
van Stam MA, van der Poel HG, Bosch JLHR, Tillier CN, Horenblas S, Mols F et al (2017) Prevalence and correlates of mental health problems in prostate cancer survivors: a case-control study comparing survivors with general population peers. Urol Oncol Semin Orig Investig. 35(8):531.e1–531.e7
12.
Fransson P (2008) Patient-reported lower urinary tract symptoms, urinary incontinence, and quality of life after external beam radiotherapy for localized prostate cancer—15 years’ follow-up. A comparison with age-matched controls. Acta Oncol (Madr) 47(5):852–861CrossRef
13.
Johnstone PAS, Gray C, Powell CR (2000) Quality of life in T1-3N0 prostate cancer patients treated with radiation therapy with minimum 10-year follow-up. Int J Radiat Oncol Biol Phys. 46(4):833–838CrossRef
14.
Thong MSY, Mols F, Kil PJM, Korfage IJ, Van De Poll-Franse LV (2010) Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden. BJU Int. 105(5):652–658CrossRef
15.
Clause-Verdreau AC, Audureau É, Leplège A, Coste J (2019) Contrasted trends in health-related quality of life across gender, age categories and work status in France, 1995-2016: repeated population-based cross-sectional surveys using the SF-36. J Epidemiol Community Health. 73(1):65–72CrossRef
16.
Kurian CJ, Leader AE, Thong MSY, Keith SW, Zeigler-johnson CM (2018) Examining relationships between age at diagnosis and health-related quality of life outcomes in prostate cancer survivors. BMC Public Health. 18(1060):1–9
17.
Pinkawa M, Fischedick K, Gagel B, Piroth MD, Asadpour B, Klotz J et al (2009) Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer. 9:1–10CrossRef
18.
Hampson LA, Cowan JE, Zhao S, Carroll PR, Cooperberg MR (2015) Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol. 68(3):480–486CrossRef
19.
Mols F, Van De Poll-Franse LV, Vingerhoets AJJM, Hendrikx A, Aaronson NK, Houterman S et al (2006) Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study. Cancer. 107(9):2186–2196CrossRef
20.
Arndt V, Koch-Gallenkamp L, Jansen L, Bertram H, Eberle A, Holleczek B et al (2017) Quality of life in long-term and very long-term cancer survivors versus population controls in Germany. Acta Oncol (Madr). 56(2):190–197CrossRef
21.
Doege D, Thong MSY, Koch-Gallenkamp L, Bertram H, Eberle A, Holleczek B et al (2019) Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany. Breast Cancer Res Treat. 175(2):499–510CrossRef
22.
Thong MSY, Koch-Gallenkamp L, Jansen L, Bertram H, Eberle A, Holleczek B et al (2019) Age-specific health-related quality of life in long-term and very long-term colorectal cancer survivors versus population controls—a population-based study. Acta Oncol (Madr). 58(5):801–10
23.
24.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85(5):365–376CrossRef
25.
van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S et al (2008) An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 44(16):2418–2424CrossRef
26.
Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. Brussels Eur Organ Res Treat Cancer, Brussels, p 3
27.
Cocks K, King MT, Velikova G, de Castro G, Martyn St-James M, Fayers PM et al (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 48(11):1713–1721CrossRef
28.
Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 16(1):139–144CrossRef
29.
Shin DW, Park HS, Lee SH, Jeon SH, Cho S, Kang SH et al (2018) Health-related quality of life, perceived social support, and depression in disease-free survivors who underwent curative surgery only for prostate, kidney and bladder cancer: comparison among survivors and with the general. Cancer Res Treat
30.
Bestmann B, Loetters C, Diemer T, Weidner W, Küchler T, Rohde V (2007) Prostate-specific symptoms of prostate cancer in a German general population. Prostate Cancer Prostatic Dis. 10(1):52–59CrossRef
31.
Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M et al (2011) Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 12:891–899CrossRef
32.
Roth AJ, Weinberger MI, Nelson CJ (2009) Prostate Cancer: Quality of life, psychosocial implications and treatment choices. Futur Oncol. 4(4):561–568CrossRef
33.
De Vibe M, Bjørndal A, Hammerstrøm KT, Kowalski K, Tipton E (2017) Mindfulness based stress reduction (MBSR) for improving health, quality of life, and social functioning in adults. Campbell Syst Rev. 11(3)
34.
Rothenberg BML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. Cancer. 19(18):3801–3807
35.
Dorey G (2007) A clinical overview of the treatment of post-prostatectomy incontinence. Br J Nurs. 16(19):1194–1199CrossRef
36.
Sprangers MA, Schwartz CE (1999) Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 48(11):1507–1515CrossRef
37.
Visser Mechteld R, Oort Frans J, van Lanschot Jan B, Van der Velden Jacobus, Kloek Jaap J, Gouma Dirk J, Schwartz Carolyn E, Sprangers MAG (2013) The role of recalibration response shift in explaining bodily pain in cancer patients undergoing invasive surgery: an empirical investigation of the Sprangersand Schwartz model. Psychooncology. 22(3):515–22
38.
Walker R, Szanton SL, Wenzel J (2015) Working toward normalcy post-treatment: a qualitative study of older adult breast and prostate cancer survivors. Oncol Nurs Forum. 42(6):E358–E367CrossRef
Metadata
Title
Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls—results from a population-based study
Authors
Salome Adam
Daniela Doege
Lena Koch-Gallenkamp
Melissa S. Y. Thong
Heike Bertram
Andrea Eberle
Bernd Holleczek
Ron Pritzkuleit
Mechthild Waldeyer-Sauerland
Annika Waldmann
Sylke Ruth Zeissig
Lina Jansen
Sabine Rohrmann
Hermann Brenner
Volker Arndt
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-05120-5

Other articles of this Issue 6/2020

Supportive Care in Cancer 6/2020 Go to the issue

Original Article

Increasing access to breast reconstruction for women living in underserved non-metropolitan areas of Australia

Original Article

Health-related quality of life and oncologic outcomes after surgery in older adults with colorectal cancer

Review Article

Systematic review of clinical practice guidelines for colorectal and anal cancer: the extent of recommendations for managing long-term symptoms and functional impairments

Original Article

“Eat to Live”-Piloting a Culinary Medicine Program for Head & Neck Radiotherapy Patients

Original Article

Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data

Original Article

Longitudinal dyadic interdependence in psychological distress among Latinas with breast cancer and their caregivers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits